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Background: Calcium needs are physiologically upregulated during pregnancy and lactation to meet demands of
the developing fetus and breastfeeding infant. Maternal calcium homeostasis is maintained by hormonal adaptive
mechanisms, thus, the role of dietary calcium supplementation in altering maternal responses to fetal-infant
demand for calcium is thought to be limited. However, increased calcium absorption is directly related to
maternal calcium intake and dietary supplementation has been suggested to prevent transient bone loss
associated with childbearing.
Methods: In a double-blind, randomized placebo-controlled trial, we randomly assigned 670 women in their
first trimester of pregnancy to 1,200 mg/day calcium (N = 334) or placebo (N = 336). Subjects were followed
through 1-month postpartum and the effect on urinary cross-linked N-telopeptides (NTx) of type I collagen,
a specific marker of bone resorption, was evaluated using an intent-to-treat analysis. Women with a baseline
and at least one follow-up measurement (N = 563; 84%) were included. Subsequent analyses were conducted
stratifying subjects by compliance assessed using pill counts. In random subsets of participants, bone-specific
alkaline phosphatase (BAP) (N = 100) and quantitative ultrasound (QUS) (N = 290) were also measured.
Results: Calcium was associated with an overall reduction of 15.8% in urinary NTx relative to placebo (p < 0.001).
Among those who consumed ≥50%, ≥67%, and ≥75% of pills, respectively, the effect was associated with 17.3%,
21.3%, and 22.1% reductions in bone resorption (all p < 0.001). There was no significant effect of calcium on
bone formation measured by BAP. However, by 1-month postpartum, those in the calcium group had significantly
lower NTx/BAP ratios than those in the placebo group (p = 0.04) indicating a net reduction in bone loss in the
supplement group by the end of follow-up. Among subjects who consumed ≥50% and ≥75% of pills, respectively,
calcium was also associated with an increase of 26.3 m/s (p = 0.03) and 59.0 m/s (p = 0.009) in radial SOS relative to
placebo by 1-month postpartum.
Conclusions: Calcium administered during pregnancy and the early postpartum period, to women with intakes
around adequacy, was associated with reduced bone resorption and, thus, may constitute a practical intervention to
prevent transient skeletal loss associated with childbearing.
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Calcium needs are physiologically-upregulated during preg-
nancy and lactation to meet the demands of the developing
fetus and breastfeeding infant for skeletal mineralization
and growth [1,2]. Maternal calcium homeostasis is main-
tained by hormonal adaptive mechanisms that control
intestinal calcium absorption, renal calcium excretion,
and mobilization of skeletal mineral stores [3,4]. The role
of dietary calcium supplementation in altering maternal
responses to fetal-infant demand for calcium is thought to
be limited; however, increased calcium absorption is dir-
ectly related to maternal calcium intake [5,6].
Pregnancy- and lactation-associated bone loss has also
been demonstrated through decreases in bone mineral
density (BMD). An estimated five percent or more of total
maternal bone mass may be mobilized [7,8], although, this
bone loss is reversible with levels rebounding to pre-
pregnancy levels after cessation of lactation [9]. There is
clear histological and biochemical evidence that the ma-
ternal skeleton undergoes increased bone resorption dur-
ing pregnancy [10,11].
Biochemical markers of bone resorption (osteoclast ac-
tivity) and bone formation (osteoblast activity) have been
found change drastically during pregnancy suggesting a
physiological state of high bone turnover [12]. These
markers of bone turnover may identify changes in bone
remodeling and microarchitecture within a relatively short
time interval (several days to months) before changes in
BMD can be detected [13] and, thus, may provide insights
into mechanisms of bone loss [14]. The long-term effects
of these transient changes in maternal bone on child bone
health are not fully understood [15], but new data indicate
that maternal dietary deficiency during pregnancy may be
associated with lower peak bone mass in offspring [16,17].
It is recommended that U.S. pregnant and breastfeed-
ing women over the age of 18 years consume at least
1,000 mg calcium per day [18], but these recommenda-
tions are based largely on studies in non-pregnant adults
[2]. High dietary calcium intake has been shown to de-
crease bone mobilization during pregnancy [19,20] sug-
gesting that dietary calcium supplementation may be an
effective means to prevent maternal bone loss. A number
of studies have demonstrated an association with calcium
supplementation and changes in bone turnover in non-
pregnant adults [21], but data on the effects among preg-
nant women are scarce and there have been relatively few
controlled supplementation trials that have studied the
relationships directly [22]. The previously published trials
of calcium supplementation and bone turnover in preg-
nant women [23-25] have been limited by their sample
sizes and varying study designs making inferences from
their results difficult. In addition, the trials in Gambia
and China studied populations with low habitual diet-
ary calcium intakes which limit their generalizabilityto populations with intakes approaching adequacy (such
as the general U.S. population).
The objective of the present study was to evaluate the ef-
fect of dietary calcium supplementation on bone turnover
during pregnancy and the early postpartum period using a
double-blind, randomized placebo-controlled trial design.
The hypothesis was that a daily supplement of 1,200 mg
calcium carbonate would decrease bone resorption over
the course of pregnancy among a relatively large sample
of women with near adequate dietary calcium intakes.
Methods
Study population and design
First trimester pregnant women were enrolled from
January 1, 2001 to April 26, 2004 at Mexican Social
Security Institute prenatal clinics which serve a low-to-
moderate income population in Mexico City. In brief,
a total of 3,836 women were assessed for eligibility, of
whom 1,981 did not meet study eligibility criteria (preg-
nancy of no more than 14 weeks gestation; not a high-risk
pregnancy; plans to reside in Mexico City for study period;
and no other reasons for exclusion) or were not able to
be reached for contact (N = 2). When pregnant women
were screened for initial recruitment, they were excluded
if they exhibited any of the following conditions: any fac-
tor that could interfere with maternal calcium metabol-
ism, intention not to breastfeed, preeclampsia, kidney or
cardiac diseases, gestational diabetes, history of urinary
infections, family or personal history of kidney stone for-
mation, seizure disorder requiring daily medications, or
ingestion of corticosteroids. Of the remaining 1,853 eli-
gible women, 670 (36%) agreed to participate, signed in-
formed consent, and were randomly assigned to receive a
daily supplement of 1,200 mg calcium carbonate (two-600
mg tablets (Lederle, Inc.); N = 334) or placebo (N = 336)
(Figure 1). Neither participants nor study personnel were
aware of treatment group assignments and placebo tablets
were formulated to be indistinguishable from the active
treatment tablets.
Calcium carbonate is ~40% elemental calcium by weight
[26]; therefore, for 1,200 mg calcium carbonate, the elem-
ental calcium equivalent is: 480 mg. All treatment and
control subjects were provided with a daily supplement
of 30 mg iron (Fe) sulfate from study entry through
12 months postpartum since prenatal vitamins were not
included in the standard of care. Women were instructed
to consume Fe supplements at the mid-day “comida”
(main meal) to decrease side effects that may accompany
Fe ingestion [27]. Supplement levels were selected to meet
two criteria: ensured adequacy and safety of total dietary
intake. Doses consistent with the AI for calcium [28] and
the Recommended Dietary Allowance (RDA) for Fe [29]
to ensure normal physiologic requirements for pregnancy
and lactation [30] would be met among women in the
Figure 1 Study sample profile.
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was suggested to be consumed at bedtime, rather than in
the morning, due to recent evidence (at the time of study
planning) of potentially greater effects on bone turnover
which was shown to be greater during the night than day-
time hours [31]. Given potential problems with compliance,
a split-dose regimen is not usually suggested for long-term
supplementation trials as simplified drug-dosing regimens
have been shown to improve adherence to therapy [32].
Participants were assessed at four time points: baseline
(1st trimester) prior to initiation of treatment, and after
having consumed calcium or placebo at 6 (2nd trimester)
and 8 (3rd trimester) months of gestation and 1-month
postpartum. Immediately following the baseline assess-
ment, women were instructed to consume tablets daily at
bedtime and compliance was assessed by pill count at each
follow-up visit. Women who had a baseline and at least
one follow-up measurement (calcium, N = 288; placebo,
N = 275) were defined as having completed follow-up and
included in this analysis (N = 563; 84%). The reasonsfor loss-to-follow up and the final numbers of women
included at each stage of the analysis are detailed in
Figure 1.
The research protocol was approved by the Human
Subjects Committees of the Mexican National Institute
of Public Health, the Mexican Social Security Institute,
and participating institutions and has complied with all
federal guidelines governing the use of human subjects.
All participants received a detailed explanation of the
study intent and procedures prior to signing the informed
consent.
Markers of bone turnover
Urinary excretion of cross-linked N-telopeptides (NTx)
of type I collagen was measured in urine from second-
morning void collected by participants prior to each
visit. NTx is a specific marker of osteoclast activity (bone
resorption) that has been shown to be stable and resistant
to degradation in stored samples [33]. Samples were ana-
lyzed with a commercially available competitive-inhibition
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International, Seattle, Washington). NTx concentrations
were controlled for urine dilution using creatinine con-
centration and expressed as nanomoles of bone collagen
equivalents (BCE) per millimole of creatinine (nM BCE/
mM creatinine). The intra-assay CV was 8.9% (at 406 nM
BCE) and 8.7% (at 1563 nM BCE); the inter-assay CV was
8.6% (at 427 nM BCE) and 5.6% (at 1513 nM BCE).
Bone-specific alkaline phosphatase (BAP) was measured
in plasma stored at −70°C from a subset of participants
(N = 100) using the Ostase® BAP immunoenzymetric assay
(Immunodiagnostic Systems Inc., Fountain Hills, AZ).
BAP levels reflect the metabolic status of osteoblasts and,
thus, serve as an indicator of bone formation [34,35].
Bone ultrasound measurement
Bone speed of sound (SOS, in meters per second) was
measured at the distal radius using quantitative ultra-
sound (QUS) (Sunlight Omnisense 7000, Zicon Ltd.
Petah-Tikva, Israel) in a random subset of participants
(N = 290). Dual-energy x-ray absorptiometry (DXA) is the
gold standard for measuring BMD [36], however, due to
the potential for ionizing radiation exposure to the fetus,
its use during pregnancy is inadvisable and specifically pro-
hibited by Mexican law. QUS allows for an inexpensive,
convenient, and radiation-free method by which to assess
bone quality during pregnancy and several previous epide-
miologic studies have used quantitative ultrasound to as-
sess bone changes over the course of pregnancy [37-39].
Dietary intake
Daily intakes of calcium and total energy were assessed
at each visit using a semi-quantitative food frequency
questionnaire designed to estimate usual dietary intake
over the prior month. The questionnaire was modified
and validated among women living in Mexico City [40]
and included questions specific to pregnancy such as any
additional use of dietary supplements.
Statistical analysis
To assess whether randomization was successful in achiev-
ing comparability, baseline characteristics were com-
pared between the calcium and placebo groups using the
Wilcoxon rank-sum (Mann–Whitney U) two-sample test
of equality. A similar comparison was performed between
those who were included in the analyses and those who
were lost to follow-up in order to assess whether selective
attrition occurred. All tests of statistical significance were
two-sided.
The effect of the calcium supplement on bone resorption
was evaluated using an intent-to-treat strategy. A first ap-
proach was to conduct a comparison of the log-transformed
NTx concentrations between treatment groups at each
follow-up stage, both unadjusted (t-test) and adjusting forcovariates (linear regression). A second approach was fit-
ting a by mixed-effects regression model with a random
intercept for each subject in order to adjust for imbalances
at baseline and to gain precision in treatment effect esti-
mates by including covariates. Mixed-effects models take
into account the correlation between repeated measures
on subjects over time. In addition, as mixed models are
flexible with respect to incomplete data, all subjects with
at least one follow-up measurement were included to in-
crease the study’s power. The outcome variable was nat-
ural log-transformed NTx in the 2nd and 3rd trimesters
and 1-month postpartum. Models included the following
baseline variables: treatment assignment (calcium vs. pla-
cebo), age (years), primigravidity (yes/no), NTx (nM BCE/
mM creatinine), daily calcium (g/day) and energy intake
(kcal/day), and time. We fitted a model including time*-
treatment interactions to test for heterogeneity of treatment
effects at different timepoints. To assess if breastfeeding at
1-month postpartum modified the effect of the supplement,
a cross-sectional model with an interaction term between
lactation (0,1 variable that defines whether the woman was
lactating at the time of the 1 month postpartum visit) and
supplement group was also fitted.
A secondary strategy was to estimate the efficacy of the
supplement by performing a dose–response analysis to
further assess the effect of the supplement by estimated
compliance. Compliance was analyzed as the proportion
of the expected number of pills taken by subjects be-
tween consecutive visits and then categorized into three
groups: ≥50% of pills consumed, ≥67% of pills consumed,
and ≥75% of pills consumed.
We also fitted a model with the NTx/BAP ratio as
the outcome variable, in the subset with both mea-
sures available (N = 100 subjects, 270 observations), to
observe if the relative levels of bone resorption-to-bone
formation changed over the course of the pregnancy and
to evaluate if this change was different between treatment
groups. All statistical analyses were performed using
STATA for Windows, version 12.0 (StataCorp LP, College
Station, Texas).
Results
A total of 670 eligible women were randomized to receive
calcium supplementation (N = 334) or placebo (N = 336)
(Figure 1). Baseline characteristics were similar for the cal-
cium and placebo groups with the exception of maternal
age which was one year higher on average in controls
(26.9 years) than in the supplement group (25.9 years; p =
0.02) (Table 1). Approximately 35.4% of women were pri-
migravid and there were no significant differences by
treatment. Dietary calcium intake, also not significantly
different between treatment groups, was about 1,100 milli-
grams per day on average. Geometric mean (and geomet-
ric standard deviation (GSD)) pre-treatment NTx levels
Table 1 Baseline characteristics of subjects by treatment assignment and follow-up status
Treatment assignment Follow-up status
Calcium Placebo Includeda Not included
(N = 334) (N = 336) (N = 563) (N = 107)
Variable Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (years) 26.9 (5.6) 25.9 (5.3)b 26.5 (5.5) 26.2 (5.3)
Education (years) 10.8 (2.9) 11.0 (3.2) 10.9 (3.1) 10.6 (2.9)
Number of pregnancies 2.0 (1.0) 2.1 (1.1) 2.1 (1.0) 2.0 (0.9)
Number of children 0.8 (0.8) 0.8 (0.9) 0.8 (0.9) 0.7 (0.7)
Number of months previous breastfeeding (cumulative lifetime) 5.6 (8.9) 6.8 (9.0) 6.4 (9.2) 5.1 (7.2)
BMI (kg/m2) 25.9 (4.1) 25.8 (3.7) 25.9 (3.9) 25.9 (3.9)
Energy intake (kcal/day) 1888 (592) 1862 (637) 1860 (613) 1951 (619)
Calcium intake (mg/day) 1108 (492) 1083 (532) 1096 (515) 1091 (497)
Hematocrit (%) 39.1 (3.3) 39.1 (3.0) 39.1 (3.2) 39.1 (2.7)
NTx (nM BCE/mM creatinine)c 62.3 (1.7) 62.9 (1.7) 62.9 (1.7) 52.2 (1.7)
aDefined as having at least one visit completed after baseline and included in final model.
bp < 0.05 Wilcoxon rank-sum (Mann–Whitney U) two sample test of equality of distributions.
cGeometric mean and GSD; n = 291 treated, n = 285 with placebo.
Table 2 Effect of calcium supplementation on NTX
(Log-transformed) (N = 563)
Unadjusted Adjusteda
N %Δb p-value N %Δb p-value
Study visit
2nd trimester 548 15.1 0.001 544 13.8 0.001
3rd trimester 517 16.4 <0.001 513 15.6 <0.001
1-month postpartum 456 20.2 <0.001 453 19.2 <0.001
Average 567 16.8 <0.001 563 15.8 <0.001
aAdjusted for baseline: age, primigravidity, NTx, and dietary calcium and total
energy intakes.
bPercent reduction: 1- eβ.
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the calcium and placebo groups, respectively (p = 0.73).
A total of 563 women (84%) had at least one follow-up
assessment and were included in the analyses. Compar-
ing those included in the analysis (placebo N = 275; cal-
cium N = 288) to those who were not included (placebo
N = 61; calcium N= 46) revealed no significant differences
by treatment assignment suggesting that those women
who remained in the study were not systematically differ-
ent than those who did not complete follow-up. Overall,
the proportion of lactating women at 1-month postpar-
tum was 89.6% and there were no differences by treatment
group (calcium, 89.9% vs. placebo, 89.3%; p = 0.8).
In the unadjusted intent-to-treat analysis, calcium was
associated with average reductions of 15.1, 16.4, and
20.2% in NTx concentrations in the 2nd and 3rd trimesters,
and 1 month post-partum respectively (all p ≤ 0.001). The
corresponding visit-specific covariate-adjusted reduc-
tion estimates were 13.8, 15.6 and 19.2% (all p ≤ 0.001)
(Table 2). The overall covariate-adjusted average reduc-
tion in NTx concentrations relative to placebo was 15.8%
(p < 0.001).
Results of the mixed effects regression model with
treatment-by-time interactions showed a significantly
different effect of the calcium supplementation on bone
resorption at each study assessment when compared to
baseline difference between treatment groups. The re-
duction was more evident at 1-month postpartum than
in the 2nd and 3rd trimesters, but these reductions were
significant for each of the three assessments: 2nd trimes-
ter (−13.7% reduction, p = 0.002); 3rd trimester (−15.6%
reduction, p = 0.001); and 1-month postpartum: (−18.6%
reduction, p < 0.001) (Figure 2).Since response to treatment could depend on baseline
dietary calcium intake, we tested a dietary calcium-by-
treatment group interaction. There was no significant
interaction between dietary calcium intake (either as a
continuous variable or as quartiles) and supplement group
at baseline. However, when examining lactation status,
there was no effect of supplement in the non-lactating
women (p = 0.57) compared to a 23% reduction in lactat-
ing women (p < 0.0001), indicating that lactation is an ef-
fect modifier for the effect of calcium supplementation on
bone resorption.
When the effect of calcium supplementation was assessed
for women “as treated” (N = 563) using models stratified
by compliance (Table 3), we saw a dose–response effect of
calcium on NTx concentration. Among those women who
consumed ≥50% of pills, calcium was associated, on aver-
age, with a 17.3% reduction in NTx in comparison to pla-
cebo (p < 0.001). This increased to 21.3% (p < 0.001) and
22.1% (p < 0.001) for those who consumed ≥67% of pills
and ≥75% of pills.
Figure 2 Effect of calcium supplementation on urinary N-telopeptides of type I collagen [NTx] (nM BCE/mM creatinine) at each trimester
during pregnancy and at 1-month postpartum (Intent-to-Treat Analysis, N = 563); adjusting for baseline variables: NTx, age, primigravidity,
dietary calcium and daily energy intake.
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(N = 100) were not significantly different than those who
did not have the measurements available (N = 463) ex-
cept for years in school (those with BAP had 0.7 more
years, on average, p = 0.04) and hematocrit (those with
BAP 0.7 percentage points higher, on average, p = 0.04).
There was no significant effect of calcium on BAP alone
at any stage (p-values: 0.61, 0.20, 0.32 for 2nd trimester,
3rd trimester, and 1-month postpartum, respectively)
(data not shown). Adjusting for age, primigravidity, base-
line dietary calcium and total energy intakes, and baseline
NTx/BAP ratio, the calcium group had lower, though
not statistically significant, NTx/BAP ratio estimates at
the 2nd (−10.1%, p = 0.32) and 3rd trimester (−13.4%, p =
0.20) visits. By 1-month postpartum, those in the calciumTable 3 Effect of calcium supplementationa on NTx by treatm
Average (Overall) 2nd trim
Compliance N (Obs) %Δc p-value %Δc
ALL 563 (1510) 15.8 <0.001 13.7
<50% 161d (270) 11.2 0.110 10.9
≥50% 505d (1240) 17.3 <0.001 14.9
≥67% 378 (790) 21.3 <0.001 19.0
≥75% 267 (423) 22.1 <0.001 25.0
aAdjusted for baseline: age, primigravidity, NTx, and dietary calcium and total energ
bCompliance assessed by pill count at each visit and analyzed as proportion of exp
cPercent reduction: 1-eβ.
dNumbers of subjects do not add to 563 because subjects may appear in more thagroup had statistically significant lower NTx/BAP ratios
than those in the placebo group (−21.5%, p = 0.04) indicat-
ing a greater net reduction in bone loss in the supplement
group by the end of follow-up.
The subset of women with SOS available (N = 290) were
not significantly different than those who did not have the
measurements available except for years in school (those
with SOS had 0.6 more years, p = 0.01) and total energy
intake (women with SOS consumed ~190 kcal less, on
average, p < 0.001). While radial SOS decreased over the
course of pregnancy in both groups, declines in the sup-
plement group were relatively attenuated and, by 1-month
postpartum, those in the supplement group had higher,
though not significantly, radial SOS than those in the
placebo group (p = 0.13) (data not shown). Calcium wasent complianceb
ester 3rd trimester 1-month postpartum
p-value %Δc p-value %Δc p-value
0.002 15.6 0.001 18.6 <0.001
0.256 10.7 0.383 12.6 0.361
0.003 15.6 0.002 19.2 <0.001
0.005 19.2 0.001 23.0 <0.001
0.171 19.0 0.006 21.9 0.002
y intakes.
ected pills used between consecutive visits.
n one stratum due to time-varying nature of compliance.
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radial SOS relative to placebo though this difference was
not significant (p = 0.216). However, among those subjects
who consumed 50% or more of pills (N = 251), calcium
was associated with an increase of 26.3 m/s in radial SOS
relative to placebo by 1-month postpartum (p = 0.03).
Among those subjects who consumed at least 75% of pills,
calcium supplementation was associated with an increase
of 59.0 m/s in radial SOS relative to placebo by 1-month
postpartum (p = 0.009).
Discussion
In this randomized controlled trial, a 1,200 mg daily cal-
cium carbonate supplement administered during preg-
nancy and the early postpartum period was associated
with reductions in NTx, compared to placebo, both during
pregnancy and at one month postpartum, indicating that
dietary calcium supplementation may help to suppress
maternal bone mobilization. These effects were stronger
with increasing treatment compliance, suggesting a dose–
response effect, with a greater than 22% average overall
reduction observed among the most compliant women.
These results are consistent with a previous randomized
crossover trial in a small group of women which showed
that dietary calcium supplementation reduced NTx levels
by an average of 14% when administered in the third tri-
mester of pregnancy [23]. To place the magnitude and dir-
ection of these changes into context, this is consistent
with a 28% reduction in urinary NTx observed after 1-
month of hormone replacement therapy among women
randomized to receive 0.625 mg conjugated equine estro-
gen (Premarin, Wyeth Ayerst, Philadelphia, PA) [41].
The results of this study are also consistent with the
findings of a study among 36 pregnant Chinese women
with low habitual dietary calcium intake that found cal-
cium supplementation was associated with significant
decreases in markers on bone resorption; although in
contrast to our findings, they also reported increases in
bone formation [25]. Unlike our study, calcium was pro-
vided by supplementing the “usual diet” with 45 g milk
powder (350 mg calcium) or milk powder plus 600 mg
calcium supplement (950 mg calcium). In that study, diet-
ary calcium supplementation during pregnancy was asso-
ciated, in a dose-dependent manner, with greater BMD
measured by DXA at 6 weeks postpartum at the spine and
whole body (p < 0.05), but not at the hip site.
In the present study, calcium was associated with sig-
nificantly higher radial SOS, a marker of bone density,
by 1-month postpartum among the most compliant sub-
jects. While the overall effect, including all subjects re-
gardless of compliance, was not statistically significant, the
direction of the effect is consistent with our hypothesis
and radial SOS measurements were available in only about
half of the subjects, thus, the study was underpowered todetect an effect of calcium on SOS. In addition, calcium’s
impact on bone density may differ depending on the type
of bone. We measured SOS in the distal radius, a site with
a predominance of cortical bone, and calcium may be act-
ing on bone sites where trabecular bone dominates.
In a study of 125 Gambian women, supplementation
with 1,500 mg/day calcium was associated with lower
BMD measured by DXA in a subset of participants at
the distal and midshaft of the radius, but with increases
in measures of BMD in the lumbar spine and whole body
[24]. Like the Chinese study, the Gambian study also
measured the effect of calcium supplementation among
women with low dietary calcium intake. However, unlike
our study and the one by Liu et al. [25], the Gambian
study did not continue supplementation into the post-
partum period which may be partially responsible for
their findings of rebound demineralization following ces-
sation of lactation [42]. We found that the ratio of bone
resorption-to-bone formation was significantly lower in
the calcium group by 1-month postpartum suggesting that
calcium is effective in reducing net bone loss measured
after pregnancy. The observed effects at 1-month postpar-
tum were being driven by lactating women in our study
which suggests that the need for continuation of calcium
supplementation may extend into the postpartum period.
A limitation of our study is that we used QUS, and
not DXA, to assess bone quality in pregnant women and
this measurement was available in only about half of the
women. QUS has been demonstrated to predict fracture
risk [43] and has been widely used in epidemiologic
studies to measure bone density particularly where DXA
is not available [44] or not advisable, such as during
pregnancy [37-39] due to the potential for radiation ex-
posure to the fetus. QUS has been found to be well-
correlated with DXA at all sites measured over 7 years
of follow-up [45] and provides our study with the advan-
tage that we were able to include repeated measures of
bone density, in addition to biochemical markers of bone
turnover, over the entire course of pregnancy and the early
postpartum period.
Pregnancy and lactation may impact a woman’s peak
bone mass which is an important determinant of subse-
quent osteoporosis risk [46]. In addition, calcium may also
have potential benefits for child bone health [16,17,47].
The possibility that intrauterine programming of fetal
bone growth may be an important determinant of osteo-
porosis and the risk of other chronic diseases in later life
is now being considered [48]. New evidence indicates that
maternal dietary deficiencies during pregnancy may be
associated with lower peak bone mass in offspring later in
life [16,17].
Average baseline dietary calcium intake for women
in our trial was within the current recommended dietary
guidelines of 1,000-1,300 mg/day for pregnant and lactating
Ettinger et al. Nutrition Journal 2014, 13:116 Page 8 of 9
http://www.nutritionj.com/content/13/1/116women [18]. It is possible that high amounts of calcium are
needed to counterbalance the nutritional needs of the de-
veloping fetus [49]; thus, previous trials among women with
low habitual dietary calcium intakes may have been unable
to detect an effect. Bone mineralization does not depend
solely on the availability of calcium: protein, energy, and
other nutrients are also important to bone formation and
mineralization. Vitamin D is essential for calcium home-
ostatis and now recognized as an important nutrient for
bone health including modest support for maternal vita-
min D status and increased offspring bone mass among
[50]. However, this study was planned and carried out on
the basis of the 1997 IOM guidelines [28]. Vitamin D was
not specifically recommended with calcium supplementa-
tion as is currently common practice. Nonetheless, other
prior studies of calcium supplementation in adult preg-
nancy [23-25], to which we compare our results, also did
not measure or administer Vitamin D. One small ran-
domized study of pregnant Brazilian adolescents with
habitually low calcium intake [51] found that 600 mg
calcium carbonate plus vitamin D3 (200 IU) resulted
in higher lumbar spine bone mass and a reduced rate of
femoral neck bone loss during lactation which is consistent
with our results. The maternal response to fetal calcium
demand may also be highly individualized and other gen-
etic, hormonal, or lifestyle factors may be involved [52].
Conclusion
In summary, dietary calcium intake likely plays a mod-
est, but important role in suppressing maternal bone
mobilization during pregnancy and the early postpartum.
Calcium supplementation during pregnancy may also
reduce the risk of hypertensive disorders of pregnancy
[53,54], pre-eclampsia [55,56], and lead exposure [57]
which themselves pose risks to the mother and fetus.
The risks posed by calcium supplementation at levels
approximating the upper limit of recommended daily in-
take are relatively minor [2,18] and U.S. guidelines for cal-
cium in pregnancy and lactation are based on studies in
non-pregnant adults [2]. The World Health Organization
now recognizes the importance of calcium supplementa-
tion in pregnancy [58]. Thus, dietary supplementation of
calcium intake among pregnant and lactating women
should be considered particularly in populations where
dietary calcium intake is low.Abbreviations
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